Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.

about

Increased depression and metabolic risk in postmenopausal breast cancer survivors Increased cardiovascular risk factors in breast cancer survivors identified by routine measurements of body composition, resting heart rate and arterial blood pressure

P2860

Q37119419-2CF35A0D-0E8A-4FAF-AD61-3BCDD00BC4CC Q37729263-3497A924-B2AF-49F9-B2BA-60A94920DADB

P2860

Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.

Item

http://www.wikidata.org/entity/Q38104812

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cardiovascular safety and hemo ...... highlights October 10th 2012.

@en

type

Item

label

Cardiovascular safety and hemo ...... highlights October 10th 2012.

@en

prefLabel

Cardiovascular safety and hemo ...... highlights October 10th 2012.

@en

P1476

Cardiovascular safety and hemo ...... highlights October 10th 2012.

@en

P2093

Boaz Mendzelevski

http://www.w3.org/2001/XMLSchema#string

Jeff Heilbraun

http://www.w3.org/2001/XMLSchema#string

Martin Braddock

http://www.w3.org/2001/XMLSchema#string

P2860

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

A quantitative analysis of kinase inhibitor selectivity

KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF

Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition.

Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention

Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.

Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

P304

783-791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2013.797407

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23651420

http://www.w3.org/2001/XMLSchema#string

P921

hemodynamics

Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.

about

P2860

P2860

Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P921